Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Gold Fields Limited (GFI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Gold Fields Limited — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Gold Fields Limited trades at $32.89 (market cap $30.01B). The key difference: Gold Fields Limited is far larger — about 6.7× ACADIA Pharmaceuticals Inc.'s market cap, and Gold Fields Limited pays a 6.91% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | GFI | |
|---|---|---|
Market Cap | $4.49B | $30.01B |
Sector | Health | Basic Materials |
52-Week High | $28.06 | $61.52 |
52-Week Low | $20.06 | $23.36 |
Enterprise Value | $3.69B | $31.46B |
Dividend Yield | — | 6.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Gold Fields (GFI) trades at $33.58, down 5.3% over 24 hours, reflecting recent bearish technical momentum. The stock shows strong fundamentals with a P/E of 8.78 and robust profitability margins, including a 40.76% net income margin. Recent earnings have been mixed, with a Q1 2025 beat but subsequent misses. Cash flow improved significantly in 2025, and the balance sheet remains solid despite rising debt levels. Analyst sentiment is divided with a 44% buy rating amid operational challenges and gold price volatility.
The outlook for GFI hinges on execution at key mines like Salares Norte and gold price stability. Upside potential exists from strong cash generation and shareholder returns, but risks include cost inflation and geopolitical pressures. The current valuation appears attractive if operational targets are met, though near-term volatility may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
